- Home
- LIPO vs GRI Comparison
LIPO vs GRI Comparison
Compare LIPO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- GRI
- Stock Information
- Founded
- LIPO 2005
- GRI 2018
- Country
- LIPO United States
- GRI United States
- Employees
- LIPO N/A
- GRI N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- LIPO Health Care
- GRI Health Care
- Exchange
- LIPO Nasdaq
- GRI Nasdaq
- Market Cap
- LIPO 3.1M
- GRI 3.2M
- IPO Year
- LIPO 2022
- GRI N/A
- Fundamental
- Price
- LIPO $2.99
- GRI $1.38
- Analyst Decision
- LIPO
- GRI Strong Buy
- Analyst Count
- LIPO 0
- GRI 2
- Target Price
- LIPO N/A
- GRI $22.00
- AVG Volume (30 Days)
- LIPO 39.2K
- GRI 358.1K
- Earning Date
- LIPO 05-14-2025
- GRI 05-15-2025
- Dividend Yield
- LIPO N/A
- GRI N/A
- EPS Growth
- LIPO N/A
- GRI N/A
- EPS
- LIPO N/A
- GRI N/A
- Revenue
- LIPO $519,866.00
- GRI N/A
- Revenue This Year
- LIPO N/A
- GRI N/A
- Revenue Next Year
- LIPO N/A
- GRI N/A
- P/E Ratio
- LIPO N/A
- GRI N/A
- Revenue Growth
- LIPO 8.88
- GRI N/A
- 52 Week Low
- LIPO $1.97
- GRI $1.10
- 52 Week High
- LIPO $12.00
- GRI $66.30
- Technical
- Relative Strength Index (RSI)
- LIPO 58.50
- GRI 39.90
- Support Level
- LIPO $2.75
- GRI $1.24
- Resistance Level
- LIPO $3.17
- GRI $1.49
- Average True Range (ATR)
- LIPO 0.29
- GRI 0.12
- MACD
- LIPO 0.02
- GRI 0.07
- Stochastic Oscillator
- LIPO 81.05
- GRI 59.52
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.